Regulatory Roundup: EMA Publishes New Transparency Policy, Releases Guideline for Biosimilar mAbs. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: EMA Publishes New Transparency Policy, Releases Guideline for Biosimilar mAbs.

ePT--the Electronic Newsletter of Pharmaceutical Technology

In European regulatory news, the European Medicines Agency (EMA) published a new policy this week regarding public access to its documents about drugs for human and veterinary use. The policy is part of EMA’s response to increasing public demand for more openness and transparency, according to a release from the agency. FDA launched the first phase of its transparency initiative early this year. The specifics of EMA’s plan include releasing documents concerning drugs after a procedure has been finalized, giving access to all business-related documents (unless there is a need to respect other privacy arrangements), and releasing non-confidential sections of documents submitted to the agency as part of a marketing authorization application such as clinical-trial reports (after the application has been finalized, that is). Any information that is confidential within marketing applications will be redacted to protect personal and commercial data. The new policy will be implemented in two phases, the first being the reactive disclosure of documents in response to written requests.

EMA also released a draft guideline last week on similar biological medicinal products containing monoclonal antibodies. The guideline specifies requirements for medicines containing mAbs that claim to be similar to another such medicine already marketed. Comments on the draft are due May 31, 2011.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here